Gonorrhea

The rates of chlamydia and syphilis declined dramatically among individuals living with HIV who were prescribed doxycycline postexposure prophylaxis, according to results of a retrospective cohort study.

For the second year in a row, the CDC’s annual STI report showed an overall decline in combined cases of the three nationally reportable infections — chlamydia, gonorrhea and syphilis.

Throughout 2024, data surrounding STDs came in waves of good and bad news, with data showing slower rates of infection and even disease elimination intermingling with news of hospitals failing to follow CDC guidance.

NEW YORK — In this video, Jacob R. McLean, DO, assistant professor of medicine at Columbia University, recaps his presentation on adolescent STI screening and treatment at the Infectious Diseases in Children Symposium.

Although reported cases remain high, there are signs the STI epidemic in the United States is slowing after years of record numbers, the CDC said Tuesday.

Less than 3% of patients tested for a bacterial STI in nearly a dozen EDs were also tested for HIV, demonstrating widespread nonadherence to a CDC recommendation, according to a study presented at IDWeek.

In June, the CDC began recommending doxycycline post-exposure prophylaxis — or doxy-PEP, as it is commonly known — as a prevention strategy for STIs in certain high-risk populations.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

Only about half of gay or bisexual men received recommended sexually transmitted infection testing at their initial visit to a private, outpatient facility, researchers reported.

The CDC has published guidance recommending that providers counsel certain patients on the harms and benefits of doxycycline for post-exposure prophylaxis — or doxy-PEP — for the prevention of sexually transmitted infections.